Navigation Links
Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Date:10/29/2009

than the similar event rates reported in the Topamax® (topiramate) label.

The label for Topamax for the prevention of migraine includes a discontinuation rate due to disturbance in attention of 3%. In addition, discontinuation rates for attention in a published study on topiramate monotherapy were 3% to 4% for doses from 96 to 192 mg (Wilding, et. al., International Journal of Obesity).

The clinical relevance of the effect of Qnexa on cognitive function is low, as demonstrated by the results from a prospective evaluation of cognitive function using RBANS (Repeatable Battery for the Assessment of Neuropsychological Status), a validated tool administered during previous clinical studies of Qnexa (OB-301 and DM-202/DM-230). Dr. Christopher Randolph, clinical professor at Loyola University Medical School in Maywood, Ill., the developer of the RBANS instrument and an expert in the assessment of cognitive function, reviewed the results of the RBANS studies. Dr. Randolph commented, "My overall impression from the RBANS data is that Qnexa at the doses tested does not appear to produce a clinically significant change in cognitive function in this patient population."

"Qnexa is a proprietary formulation of controlled release topiramate and phentermine. As evidenced by the high retention and low dropout rates in the pivotal trials, we believe the reduced Cmax of topiramate, in the presence of phentermine, has a beneficial net effect on centrally mediated adverse events such as attention, as compared to commercially available topiramate formulations," stated Wesley Day, vice president of clinical development of VIVUS.

"The integrated safety summary for the year-long studies showed that discontinuation rates due to cognitive side effects were minimal as no MedDRA preferred term associated with cognitive effects resulted in discontinuation in more than 1% of subjects. Previous studies of topiramate monotherapy have
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)... 2015  In today,s ever-changing marketplace, call centers must ... increasingly connected, and increasingly impatient with slow service. The ... channels and tools is driving call centers to explore ... According to research by benchmarking firm, Best Practices, ... in a call center study realize the impact of ...
(Date:7/31/2015)... NEW YORK , July 31, 2015  Seeger Weiss ... Drug Administration (FDA) issued a warning letter to C.R. Bard, ... for not taking adequate strides to correct violations the agency ... aware of these violations after the FDA cited them during ... 05, 2015, in Bard,s Tempe, AZ , ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... , ... PTC Therapeutics, Inc. (PTC) today announced the initiation of an ... men with nonsense mutation Duchenne/ Becker muscular dystrophy (nmDBMD) ... trial is evaluating the best methods for measuring functional abilities ...
... , , OXFORD, England , ... focused on allergy, today announced that it has,initiated phase II ... cat allergies. With the start of these studies, and the ... company,now has three clinical development programmes in phase II. Each ...
Cached Medicine Technology:PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 5PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 6Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies 2Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies 3
(Date:8/1/2015)... ... August 01, 2015 , ... The condition where veins are enlarged and ... often causing pain and discomfort. Those who spend a lot of time on their ... Vein Center is doing what it can to create awareness and provide a cure ...
(Date:8/1/2015)... ... August 01, 2015 , ... Calvary Hospital today announced that it ... Bronx campus. The goal is to bring this Torah – dating from 1880 – ... rituals and religious services. , Scroll No. 515, from the town of Taus-Domazlice, ...
(Date:8/1/2015)... ... ... Tina Wilcoxson, owner of Freeport Maine’s Royal River Natural Foods, was named one ... Federation, the largest retail trade association in the world, for her “advocacy and engagement” ... named as such. According to the NRF’s website, Retail Champions are “Main Street business ...
(Date:8/1/2015)... ... ... Brig and Lita Hart, icons of the network marketing industry and founders of ... the HOPE Movement of EvolvHealth. In what has been a long-term relationship between the ... their missions of purpose together to change the course of the network marketing industry. ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Local Retail Advocate Wins National Recognition 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2
... supporters will discuss implications of federal health-reform bills at the ... at 9:00 am. Health-policy experts will examine which proposed legislation ... will make sure Americans are not forced to have a ... cradle to grave and that citizens are not forced to ...
... Pa., June 17 The GBS/CIDP Foundation International, ... afflicted with Guillain-Barre Syndrome (GBS), Chronic Inflammatory Demyelinating ... Patricia A. Bryant to the position of Executive ... succeeds Estelle L. Benson, who along with her ...
... (June 17, 2009) Two new studies published by ... demonstrate a need for more vigilant monitoring for seizure ... subtle seizures that are typically unrecognized. These subtle seizures ... damage, death and severe disability. Published in recent ...
... A $4.15 million, four-year National Institutes of Health grant ... Medicine to conduct the first health study of teenage ... Dennis Fortenberry, M.D., M.S., professor of pediatrics in the ... follow 72 males, ages 14-17 years, for three years. ...
... , CiNet Acquires Industry-Leading Training Assets to Help ... Workplace Efficiency , , DALLAS, June 17 ... emerging eLearning company serving customers across the public ... the formal launch of its business operations. ...
... also guards against infection, study shows , WEDNESDAY, June ... development of emphysema also defends the lungs against bacterial ... thought that the only thing macrophage elastase, matrix metalloproteinase-12 ... the tissue destruction seen in emphysema patients. , "But ...
Cached Medicine News:Health News:GBS/CIDP Foundation International Appoints Patricia A. Bryant as Executive Director 2Health News:New findings encourage more vigilant monitoring of seizure activity among intensive care patients 2Health News:New findings encourage more vigilant monitoring of seizure activity among intensive care patients 3Health News:Cellular telephones to expand knowledge of health behaviors and microorganisms in adolescent males 2Health News:Critical Information Network (CiNet(TM)) Launches to Provide eLearning Solutions to Public Safety, Healthcare and Industrial Operations Professionals 2Health News:Critical Information Network (CiNet(TM)) Launches to Provide eLearning Solutions to Public Safety, Healthcare and Industrial Operations Professionals 3Health News:Lung Enzyme Both Friend and Foe 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: